Shin Nippon Biomedical Laboratories Management

Management criteria checks 1/4

Shin Nippon Biomedical Laboratories' CEO is Ryoichi Nagata, appointed in Jan 1991, has a tenure of 33.25 years. directly owns 2.46% of the company’s shares, worth €9.11M. The average tenure of the management team and the board of directors is 1.8 years and 8.8 years respectively.

Key information

Ryoichi Nagata

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	33.3yrs
CEO ownership	2.5%
Management average tenure	1.8yrs
Board average tenure	8.8yrs

Recent management updates

Recent updates

CEO

Ryoichi Nagata (65 yo)

33.3yrs

Tenure

JP¥144,061,000

Compensation

Dr. Ryoichi Nagata, M.D., Ph D., F.F.P.M., serves as President & Director of Satsuma Pharmaceuticals, Inc. since June 8, 2023 Also serves as it's Chief Executive Officer. He has been the President of Shin...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ryoichi Nagata	Chairman	33.3yrs	JP¥144.06m	2.46% ¥ 9.1m
Fumihiko Makino	Senior Executive Officer	2.3yrs	no data	no data
Toshiyuki Iwata	Managing Executive Officer and GM of IR Public Relations Department & Sustainability	1.3yrs	no data	no data
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	1.8yrs	no data	no data
Kyomi Nagatoshi	Managing Executive Officer	no data	no data	no data
Ken Takanashi	Executive VP of Group Corporate Management & Global Business & Director	19.8yrs	no data	0.088% ¥ 326.3k
Satoshi Matsumoto	Managing Executive Officer & GM of Fisheries Division	less than a year	no data	no data
Hideshi Tsusaki	Senior MD	1.3yrs	no data	no data
Terumasa Hirai	Managing Executive Officer	no data	no data	no data
Eishi Tsunozaki	Senior MD & Director	no data	no data	0.043% ¥ 161.0k
Ichiro Nagata	Executive VP	no data	no data	37.87% ¥ 140.2m
Takashi Iriyama	Managing Executive Officer and GM of Corporate Strategy Headquarters & Corporate Planning Department	no data	no data	no data

1.8yrs

Average Tenure

56yo

Average Age

Experienced Management: YB3's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Ryoichi Nagata	Chairman	41yrs	JP¥144.06m	2.46% ¥ 9.1m
Shinji Nitanda	Senior MD of Corporate Development & Corporate Tax Administration and Director	13.8yrs	no data	no data
Kyomi Nagatoshi	Managing Executive Officer	no data	no data	no data
Ken Takanashi	Executive VP of Group Corporate Management & Global Business & Director	21.3yrs	no data	0.088% ¥ 326.3k
Hideshi Tsusaki	Senior MD	9.8yrs	no data	no data
Eishi Tsunozaki	Senior MD & Director	9.8yrs	no data	0.043% ¥ 161.0k
Ichiro Nagata	Executive VP	3.8yrs	no data	37.87% ¥ 140.2m
Shinichi Fukumoto	Independent Outside Director	8.8yrs	no data	no data
Takashi Yamashita	Independent Outside Director	8.8yrs	no data	no data
Masakazu Suda	Full-Time Auditor	3.8yrs	no data	0.015% ¥ 56.0k
Tsuyoshi Hanada	Independent Outside Director	3.8yrs	no data	0.0079% ¥ 29.4k
Keiko Totani	Independent Outside Director	2.8yrs	no data	no data

8.8yrs

Average Tenure

59yo

Average Age

Experienced Board: YB3's board of directors are considered experienced (8.8 years average tenure).

Shin Nippon Biomedical Laboratories Management

Management criteria checks 1/4

Key information

Recent management updates

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

No independent directors

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Recent updates

Upcoming dividend of JP¥30.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2024 Results on May 08, 2024

Third quarter 2024 earnings released: EPS: JP¥19.89 (vs JP¥1.63 loss in 3Q 2023)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

New minor risk - Share price stability

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2024 Results on Feb 02, 2024

Investor sentiment deteriorates as stock falls 16%

Second quarter 2024 earnings released: EPS: JP¥38.26 (vs JP¥59.45 in 2Q 2023)

Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending 2024

Upcoming dividend of JP¥20.00 per share at 2.6% yield

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2024 Results on Nov 07, 2023

Investor sentiment improves as stock rises 17%

First quarter 2024 earnings released: EPS: JP¥32.99 (vs JP¥46.70 in 1Q 2023)

Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. (NasdaqGM:STSA) from a group of sellers.

Now 20% undervalued after recent price drop

Full year 2023 earnings released: EPS: JP¥146 (vs JP¥171 in FY 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 27, 2023

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of JP¥30.00 per share at 1.4% yield

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: JP¥1.63 loss per share (vs JP¥41.89 profit in 3Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Investor sentiment deteriorated over the past week

No independent directors

Second quarter 2023 earnings released: EPS: JP¥59.45 (vs JP¥40.28 in 2Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2023

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: JP¥46.70 (vs JP¥43.86 in 1Q 2022)

Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Guidance for the Six Months Ending September 30, 2022 and Fiscal Year Ending March 31, 2022

Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) made a tender offer to acquire Ina Research Inc. (TSE:2176) from its shareholder for ¥2.7 billion.

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: JP¥171 (vs JP¥87.94 in FY 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Year End Dividend Guidance for the Year Ending March 31, 2023

Shin Nippon Biomedical Laboratories, Ltd., Annual General Meeting, Jun 28, 2022

No independent directors

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2022 Results on May 06, 2022

Upcoming dividend of JP¥40.00 per share

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shin Nippon Biomedical Laboratories, Ltd. Provides Special Dividend Guidance the Year Ending March 31, 2022

Second quarter 2022 earnings released: EPS JP¥40.28 (vs JP¥11.91 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS JP¥43.86 (vs JP¥15.45 in 1Q 2021)

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2021 and Year Ending March 31, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS JP¥87.94 (vs JP¥61.25 in FY 2020)

Upcoming dividend of JP¥5.00 per share

Shin Nippon Biomedical Laboratories, Ltd. to Report Fiscal Year 2021 Results on May 10, 2021

New 90-day low: €4.86

Third quarter 2021 earnings released: EPS JP¥8.10 (vs JP¥17.49 in 3Q 2020)

New 90-day high: €5.70

Shin Nippon Biomedical Laboratories, Ltd. to Report Q3, 2021 Results on Feb 05, 2021

New 90-day low: €4.96

New 90-day low: €5.25

Second quarter 2021 earnings released: EPS JP¥11.91

New 90-day high: €6.65

Shin Nippon Biomedical Laboratories, Ltd. to Report Q2, 2021 Results on Nov 06, 2020

First quarter earnings released

Shin Nippon Biomedical Laboratories, Ltd. to Report Q1, 2021 Results on Aug 07, 2020

CEO

Tenure

Compensation

Leadership Team